Possible involvement of copper(II) in Alzheimer disease. by Kowalik-Jankowska, Teresa et al.
Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 869
Alzheimer disease (AD) is principally a disease
of the elderly, although there are small numbers
of familial cases. With age, a greater percentage
of the population develops the disease, so that
by their mid-80s, some 50% of people show
signs of AD (1). AD is manifested by a series of
clinical features. One feature is an impairment
of memory, with recent and immediate recall
being affected more than remote recall.
Another is the loss of ability to perform previ-
ously learned complex tasks. Equally sympto-
matic is the loss of ability to reason.
At the tissue level, the disease is character-
ized by three typical abnormalities. One is a
profound loss of nerve cells inside the brain.
The second pathological feature of the disease is
microscopic. Fibrous proteins accumulate
inside the nerve cells within the cortex of the
brain, forming dense mats called neuroﬁbrillary
tangles. The neurofibrillary tangles are com-
posed of a phosphorylated form of tau protein
(a cytoskeletal protein, i.e., a protein that nor-
mally forms the structure within a cell) (2). The
third feature is currently central to research of
senile plaques. This is an aggregation of ﬁbrous
proteins in the extracellular space, the area out-
side a cell and between other cells. Principal
among the fibrous proteins in the amyloid
plaques is a small protein composed of approxi-
mately 39–43 amino acids, known as the
β -amyloid (Aβ ) peptide (3). The Aβ peptide is
derived from the larger amyloid precursor
protein (APP), a 563–770-residue membrane
protein, as a normal cleavage product (4).
APP metabolism and processing have been
extensively studied, with rats and mice as the
most widely used laboratory animal species.
However, their Aβ region contains three
amino acid substitutions (Arg5 → Gly, Tyr10
→ Phe, His13 → Arg) compared with human
Aβ peptide (5). These changes have been
shown to alter the structure and properties of
the Aβ peptides (6) as well as processing of
APP. These sequence alternations are most
likely responsible for the virtual absence of Aβ
deposits in normal or aged rodent brain (7).
The importance of Aβ sequence conservation
is further strengthened by the occurrence of
Aβ deposits in the brains of aged primates,
polar bears, and dogs, all known to possess
sequence identity to human Aβ peptide (8).
Copper and AD
There is substantial interest in the role of
copper, manganese, irons, and other redox-
active transition metals in the neuropathol-
ogy of neurodegenerative disorders such as
Parkinson disease, AD, and amyotrophic lat-
eral sclerosis. These metals are essential in
most biological reactions. However, their
excessive tissue accumulation can be cytotoxic,
in particular because perturbations in metal
homeostasis result in an array of cellular dis-
turbances characterized by oxidative stress and
increased free radical production (9).
The ability of copper to cycle between sta-
ble oxidized Cu2+ and unstable reduced Cu+
states is used by cuproenzymes involved in
redox reactions (e.g., Cu/Zn superoxide dis-
mutase and cytochrome oxidase). However,
the Cu2+ ↔ Cu+ transitions can in certain cir-
cumstances also result in the generation of
reactive oxygen species (e.g., superoxide radi-
cal and hydroxyl radical), which, if not detoxi-
ﬁed efﬁciently, can damage susceptible cellular
components. Copper can also bind with high
affinity to histidine and cysteine residues of
proteins, which can result in their inactiva-
tion. The need to provide copper without the
ensuing cellular toxicity has necessitated evo-
lution of tightly regulated copper homeostatic
mechanisms (10). The brain contains the sec-
ond highest cellular concentration of copper
in the body, next to the liver. Copper is most
concentrated in the gray matter (60–110 µM),
which is consistently higher than in white
matter (25–79 µM) (11,12). 
The homeostasis of zinc, copper, and iron,
and their respective binding proteins is signiﬁ-
cantly altered in the AD brain (12,13).
Increased concentrations of copper, iron, and
zinc are detected in the neuropil of the AD-
affected brain, where they are highly concen-
trated within amyloid plaques and reach
concentrations of up to 0.4 mM for Cu and
1 mM for Fe and Zn (12). The observation
that Cu/Zn-selective chelators enhance solu-
bility of Aβ peptide from postmortem brain
tissue of AD patients and transgenic mouse
brains (14) suggests that these metal ions may
play a role in cerebral amyloid assembly.
Copper is probably not an initiator of AD but
interacting with APP or its fragments may
contribute to the disease development.
APP can reduce Cu2+ to Cu+ in a cell-free
system, potentially leading to increased oxida-
tive stress in neurons (15). This copper
ion–mediated redox reaction led to disulﬁde
bond formation in APP, which indicated that
free sulfhydryl groups of APP are involved. Five
years after the initial identiﬁcation of the amino
acid residues involved in the redox reaction,
Ruiz et al. conﬁrmed that cysteine 144 is a key
residue in the reduction of Cu2+ to Cu+ by sol-
uble APP (15,16). The studies have also shown
that copper binding to APP protein in cysteine-
rich regions requires the presence of histidine
residues. Treatment of neuronal cultures with a
peptide corresponding to the human APP cop-
per-binding domain (APP142–166) potenti-
ated copper but not Fe or Zn toxicity.
Incubation of APP142–166 with low-density
lipoprotein (LDL) and copper resulted in
significantly increased lipid peroxidation
compared with copper and LDL alone. 
Potentially, APP–Cu+ complexes may be
involved in reducing hydrogen peroxide to
form an APP–Cu2+–hydroxyl radical interme-
diate (17). Analysis of the specific reaction
revealed the generation of C-terminal polypep-
tides containing the Aβ domain. The results
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suggest that a cytotoxic gain of function of
APP–Cu+ complexes in the redox reaction
with H2O2 might result in a perturbation of
free radical homeostasis and/or lead to an accu-
mulation of oxidized protein that is known to
be associated with AD (18).
The Aβ peptide is a normal soluble com-
ponent of the plasma and the cerebrospinal
ﬂuid (19). The observation of amyloid deposits
in senile plaques in essentially all cases of AD
led to the hypothesis that conversion of soluble
Aβ into insoluble ﬁbrils is critical for the onset
of the disease (20). This hypothesis is sup-
ported by the fact that fresh Aβ peptide is non-
toxic to cultured neurons, whereas aged Aβ
(incubated to form amyloid fibrils) becomes
toxic (21). The studies clearly demonstrate ele-
vated copper levels within neuropil of the cor-
tical and accessory basal nuclei of the amygdala
compared with control neuropil, and a further
signiﬁcant elevation of plaque deposits within
the core and periphery (12). 
The results support the interactions of
Cu(II) with Aβ because treatment with a cop-
per chelator markedly and rapidly inhibits Aβ
accumulation in AD transgenic mice (22).
Cu(II) induces Aβ aggregation under mildly
acidic conditions (e.g., pH 6.8–7.0, such as
that believed to occur in the AD brain) (23).
Rat Aβ 1–40 and histidine-modified human
Aβ 1–40 were not aggregated by Cu2+, indi-
cating that histidine residues are essential for
metal-mediated Aβ assembly and perhaps
explaining why these animals do not form
cerebral Aβ (23). Through the use of syn-
thetic peptides corresponding to the first 28
residues of human Aβ , rat Aβ , and single-
residue variations, it was revealed that the
substitution of Arg for His13 is responsible
for the different Zn2+-induced aggregation
behaviors of rat and human Aβ . The coordi-
nation of Zn2+ to His13 is critical to the Zn
ion–induced aggregation of Aβ (24). 
There are three histydyl residues in the Aβ
molecule (His6, His13, His14). Raman spec-
troscopy studies revealed that all three His
residues of Aβ are involved in the interactions
with Cu2+ ions (25). Analysis of the Raman
spectra has revealed two different modes of
metal–Aβ binding. One is characterized by
metal binding to the imidazole Nτ of histidine,
which produces insoluble aggregates; the other
involves metal binding to the Nπ atom of histi-
dine as well as to main-chain amide nitrogens,
resulting in the formation of soluble com-
plexes. This transition from one binding mode
to the other explains the strong pH depen-
dence of Cu(II)-induced Aβ aggregation.
The afﬁnity of copper for Aβ 1–42 is seven
orders of magnitude higher than for Aβ 1–40
(26), most likely due to a higher β -sheet con-
tent of Aβ 42, because this conformation fre-
quently mediates high-afﬁnity copper binding
of cuproproteins (27). Human Aβ directly
produces hydrogen peroxide (H2O2) by a
mechanism that involves the reduction of
Cu(II), setting up conditions for Fenton—type
chemistry (28). The metal-reducing activity
and H2O2 production of Aβ species follow the
order Aβ 42human > Aβ 40human > Aβ 40mouse ≈
0, corresponding to the neurotoxicity and the
participation of the native peptides in amyloid
pathology (28).
The studies on the binding abilities of the
various fragments of human and mouse Aβ
peptide with Cu2+ (fragments 1–6, 1–9, 1–10,
11–16) (29,30) have shown that tyrosine
residue in the 10th position of the human frag-
ment does not take part in the coordination of
the metal ion. The presence of the bulky argi-
nine residue in the 5th position of the peptide
sequence of the human fragments changes the
coordination ability of the peptide. The pres-
ence of histidine residue in the 13th position
of human fragment changes the coordination
mode of Cu(II) ions compared with the mouse
fragment. The human fragment of Aβ peptide
is much more effective in Cu(II) ion binding
than the mouse fragment because of the pres-
ence of the His–His sequence (30). These dif-
ferences in the coordination modes of Cu(II)
ions may inﬂuence Cu(II) ion–catalyzed oxida-
tion of these peptides by hydrogen peroxide
(31). The involvement of free radicals in the
pathogenesis of AD is now widely accepted for
many reasons (e.g., Aβ is sensitive to the action
of free radicals) (32).
Further studies of Cu(II) complexes with
longer fragments (1–16, 1–28, 11–28) of
human and mouse Aβ peptide are currently
in progress in our laboratory and will be
reported soon.
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